Status:
COMPLETED
Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment
Lead Sponsor:
Region Skane
Collaborating Sponsors:
Crafoord Foundation
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
For patients with advanced heart failure, Cardiac Resynchronization Therapy (CRT) has been a major improvement. The treatment improves symptoms and prolongs life in selected patients with heart failur...
Eligibility Criteria
Inclusion
- Symptomatic heart failure (New York Heart Association functional class II - IV) despite stabile optimal medical therapy.
- Wide QRS ≥ 120 milliseconds on standard ECG.
- LV systolic dysfunction (EF ≤ 35%).
- Written informed consent.
- Accepted for CRT-P or CRT-D treatment
Exclusion
- Life expectancy \< 12 months.
- Recent myocardial infarction (\< 3 months).
- Significant valve disease
- Chronic atrial fibrillation
- Pregnancy
- Severely impaired renal function (estimated glomerular filtration rate (eGFR) \< 30 ml/min)
- Unable to give written informed consent.
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01426321
Start Date
August 1 2011
End Date
December 1 2018
Last Update
March 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skane University Hospital
Lund, Sweden, 221 85